Blog
Go Gray in May for Brain Tumor Awareness
by Zara Jethani
Raise awareness for brain tumor treatment and research by wearing GRAY ribbons, clothes, and masks. Be sure to help spread the word to friends, family, and colleagues. A Few Facts about Brain Tumors Approximately 80% of cancers may metastasize to the brain, these include melanoma (where nearly 50% of cases will...
Pacific Neuroscience Institute Physicians Named “L.A.’s Top Doctors” of 2021
by Zara Jethani
This year, seven of Pacific Neuroscience Institute Medical Group’s physicians were included in Los Angeles Magazine’s April 2021 roster of “L.A.’s Top Doctors.” The results were based on a Los Angeles Magazine survey that asked physicians throughout Los Angeles County to identify the doctors they considered to be...
ONCOLOGY Clinical Trials Round-Up: March 2021
by Mini Gill
New Studies EpicentRx Beta-Prime: A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects with Refractory Solid Tumors (NCT04673942) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade...
New Hope on Vanquishing Glioblastoma | Dr. Santosh Kesari
by Anthony Effinger
Listen to our conversation with Dr. Kesari to find out what GBM treatments make him believe that big breakthroughs are on the horizon for treating this tricky, and tragic, disease.
PNI Founders’ Message 2021
by Guest Author
Although our medical community continues to strain under the burden of COVID-19, there has been hope, determination and progress. Neurological diseases do not stop and neither have we at Pacific Neuroscience Institute.
Clinical Trials Round-Up: December 2020
by Mini Gill
New Studies Blue Earth Diagnostics FLC-219: (PDF): An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy (PURSUE) (NCT04410367) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A...
Clinical Trials Round-Up: November 2020
by Mini Gill
Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...
Clinical Trials Round-Up: October 2020
by Mini Gill
Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...
PNI’s Super Doctors 2021!
by Zara Jethani
Nineteen of PNI’s doctors have been recognized as Super Doctors in the 2021 announcement of this prestigious industry standard award. Of note, Daniel F. Kelly, MD, Founder and Director of PNI, and expert neurosurgeon became a Hall of Fame Super Doctor. With his selection to...
Clinical Trials Round-Up: September 2020
by Mini Gill
Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience ( PDF ): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma ( NCT03463265 ) Orbus Therapeutics ( PDF ): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...
Last updated: June 6th, 2022